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A novel plant sesquiterpene lactone derivative, DET derivative (DETD)-35, originating
from parental deoxyelephantopin (DET) was previously observed to effectively suppress
human triple negative breast cancer (TNBC) MDA-MB-231 cell activity and tumor
growth in mice. In this study, the mechanisms underlying the activity of DETD-35
were elucidated. DET and DETD-35 induced reactive oxygen species (ROS) which
caused structural damage and dysfunction of mitochondria and increased cytosolic
calcium level, subsequently evoking exosome release from the cancer cells. Intriguingly,
exosomes induced by both compounds had an atypical function. Cancer cell-derived
exosomes commonly show metastatic potential, but upon DET/DETD-35 treatment
exosomes showed anti-proliferative activity against MDA-MB-231 cells. Quantitative
proteome analysis of TNBC cell-secreted exosomes showed that DET and DETD-35
attenuated the expression of proteins related to cell migration, cell adhesion,
and angiogenesis. Furthermore, several exosomal proteins participating in biological
mechanisms such as oxidative stress and decrease of transmembrane potential of
mitochondria were found deregulated by treatment with either compound. Pretreatment
with ROS scavenger, N-acetylcysteine, blockaded DET− or DETD-35−induced
oxidative stress and calcium dependent exosome release mechanisms, and also
reverted DET− or DETD-35−induced reprogramming exosomal protein expression
profiles resulting in attenuation of exosomal toxicity against TNBC cell proliferation. In
summary, this study shows that a plant-derived sesquiterpene lactone DET and its
analog DETD-35 inhibitory TNBC cell activities through oxidative stress-induced cancer
cell releasing exosomes in tandem with alteration of exosomal protein composition and
functions. The findings of this study suggest that DETD-35 may be suitable for further
development into an anti-TNBC drug.
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INTRODUCTION
Triple negative breast cancer (TNBC) is a breast cancer subtype
lacking expression of estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor
2 (HER2) and accounts for about 15–25% of total breast
cancer patients (Jamdade et al., 2015). TNBC commonly has a
high recurrence rate in the first 3 years after diagnosis, worse
prognosis, high risk of distant visceral metastasis, and is often
observed in younger patients (Morris et al., 2007; Ovcaricek
et al., 2011). Since the tumor cells are deficient in the necessary
receptors, common hormone therapy or target therapies are
inefficient, and therefore a combination of chemotherapy
drugs are often used on TNBC patients; however, such a
therapeutic approach cannot circumvent chemotherapy-induced
drug resistance and adverse side effects in cancer patients
(Chougule et al., 2011; von Minckwitz and Martin, 2012). Thus
there is need to develop novel intervention approaches or
therapeutic agents with minimal toxicities or better efficacy for
TNBC patients.
Exosomes are nanoscale (40–100 nm diameter) membrane-
bound vesicles specialized for long distance intercellular
communication, facilitating the delivery of cargo proteins,
mRNA, miRNA, etc. into target cells (Corrado et al., 2013).
Exosomal proteomes from different origins contain a conserved
set of common proteins for exosomal biogenesis, structure, and
trafficking, and a specific subset of proteins associated with cell
type-related functions (Raimondo et al., 2011; Choi et al., 2015).
Cancer cell-derived exosomes can elicit pre-metastatic niche
formation to promote cancer metastasis. For example, pancreatic
cancer-derived exosomes promote liver metastasis by generating
an immune cell infiltrated fibrotic microenvironment that favors
metastasis (Zhang and Wang, 2015). In addition, cancer cells can
impart an oncogenic environment by manipulating surrounding
cells via exosomes (Melo et al., 2014). Deciphering a cell-type
specific set of exosomal proteins may offer an ideal option for
the development of exosome-based biomarkers and therapies.
Intrinsically, exosomes possess the ability to cross biological
barriers; therefore, exosome-encapsulated drug or bioactive
natural product formulation are considered to be a versatile
strategy for treating cancers or other inflammatory disorders
(Zhuang et al., 2011; Haney et al., 2015; Ha et al., 2016).
Developing plant-derived phytocompounds as potential
chemotherapeutic or chemopreventive agents for human
cancers has generated a great deal of research interest. In our
previous studies, we identified deoxyelephantopin (DET), a
major germacranolide sesquiterpene lactone isolated from a
perennial medicinal herb Elephantopus scaber L., which shows
polypharmacological activities against TS/A(ER+) mammary
tumor cell growth and metastasis. The anti-TS/A cancer cell
activity of DET is through ROS/c-Jun N-terminal kinases
(JNK)-mediated apoptosis, deregulation of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB)/IκB
kinase (IKK) pathways and ubiquitin-proteasome machinery,
which impedes cancer cell motility by inhibiting calpain-
mediated adhesion dynamics, and formation of centrosomal
aggregates among others (Huang et al., 2010; Lee et al., 2010; Lee
and Shyur, 2012). DET also showed pleiotropic function against
lipopolysaccharide/D-galactosamine (LPS/D-GalN)−induced
fulminant hepatitis by attenuating proinflammatory macrophage
infiltration and cytokines, cyclooxygenase-2 (COX-2), and
inducible nitric oxide synthase (iNOS) expression (Huang et al.,
2013). However, relatively less inhibitory activity was found for
human TNBC cell line, MDA-MB-231, a highly metastatic breast
cancer type. Recently, we modified the DET structure to create
novel DET derivatives (DETDs) by semi-organic synthesis,
and obtained a number of bioactive DETDs. Among these
derivatives, DETD-35 showed the best suppression of tumor
growth and lung metastasis in MDA-MB-231 tumor-bearing
NOD.CB17-Prkdcscid/NcrCrl (NOD/SCID) mice compared to
the parental DET (Nakagawa-Goto et al., 2016). The underlying
molecular mechanisms remains unexplored.
Cancer cell-derived exosomes have been demonstrated to play
a role in promoting cancer cell invasiveness and metastasis,
and activation of relevant oncogenic pathways (Higginbotham
et al., 2011; Urbanelli et al., 2013; Ciardiello et al., 2016).
Very recently, we have observed that DET and DETD-35 can
induce ROS production in the MDA-MB-231 cells (Shiau et al.,
2017). We thus hypothesized that there might be an association
between ROS production and exosome release/activities, and
these activities may be triggered by DET and/or DETD-35 as a
mechanism for suppression of TNBC cell activities. Therefore,
to shed light on the molecular mechanisms through which
DET and DETD-35 suppress TNBC cell activity, in this study,
we investigated whether TNBC cell-derived exosomes and
their cargo proteins are affected by DET and/or DETD-35
treatment. We observed that both DET and DETD-35 can indeed
significantly enhance MDA-MB-231 cell secretion of exosome
vesicles into media. Of note, both compounds induced ROS
production and calcium ion flux in cancer cell cytosols could
impact exosome release. Unexpectedly, exosomes collected from
DET− or DETD-35−treated cancer cells showed a significant
inhibitory effect on the same recipient TNBC cells. A comparative
exosome proteome study revealed a group of oxidative stress and
mitochondrial function-related proteins which were commonly
or differentially regulated by DET or DETD-35, revealing the
novel molecular mechanisms of both compounds against TNBC
cells.
MATERIALS AND METHODS
Chemicals and Antibodies
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), dimethyl sulfoxide (DMSO), ionomycin, 4,6-diamidino-
2-phenylindole (DAPI), N-acetyl-L-cysteine (NAC),
DL-dithiothreitol (DTT), 1,2-bis(2-aminophenoxy)ethane-
N,N,N′,N′-tetraacetic acid tetrakis (acetoxymethyl ester)
(BAPTA-AM), and iodoacetamide (IAA) were purchased from
Sigma-Aldrich. Amplex Red acetlycholinesterase (AChE) assay
kit, MitoProbe 1,1′,3,3,3′,3′-hexamethylindodicarbocyanine
iodide [DiIC1(5)], and Fluo-4 AM were purchased from Thermo
Fisher Scientific. DMEM, fetal bovine serum (FBS), and the
antibiotics mixture (penicillin-streptomycin) were purchased
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from Invitrogen. Primary antibodies against voltage-dependent
anion channel 1 (VDAC1), tumor susceptibility gene 101 protein
(tsg101), CD9 and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Santa Cruz Biotechnology), HSP27 (GeneTex), and
β-actin (Chemicon, Millipore) were used.
Preparation of DET and Its Derivative
DETD-35
The extraction and identification of plant DET compound from
the traditional medicinal herb E. scaber L. followed the protocol
reported by Huang et al. (2010). The synthesis of DETD-35
followed the method described by Nakagawa-Goto et al. (2016).
The chemical purity of DET and DETD-35 were>99% as judged
by NMR spectrometry.
Cell Culture
Human TNBC MDA-MB-231 cells obtained from ATCC, United
States were grown in the manufacturers’ suggested medium
supplemented with 10% FBS, 1 mM sodium pyruvate (Gibco) and
100 units/mL penicillin, and incubated in a humidified 5% CO2
incubator at 37◦C.
Isolation and Characterization of
Exosomes
MDA-MB-231 cells (4 × 106 cells/dish) were grown in a 15 cm
dish using exosome-depleted medium and incubated overnight
to allow cell adhesion. The medium was then replaced with fresh
exosome-depleted medium, and subsequently TNBC cells were
cultured for the indicated time periods (4, 8, and 12 h). Exosomes
were collected from several runs of ultracentrifugation based on a
published protocol with some modifications (Théry et al., 2006).
Briefly, the culture medium was collected and centrifuged at
300 × g and 2000 × g for 10 min at 4◦C to exclude dead cells.
The supernatant was further centrifuged at 16500× g for 30 min
at 4◦C to eliminate cell debris contamination. The exosomes
were then pelleted through ultracentrifugation at 120,000 × g
for 120 min at 4◦C. The exosome pellet was washed using PBS
buffer, and ultracentrifuged at 120,000 × g for 120 min again
to remove the contaminating proteins. The exosome pellet was
re-dissolved in the PBS buffer and stored at −80◦C. Finally,
the quantification of exosomes derived from TNBC cells was
performed using Amplex Red acetlycholinesterase (AChE) assay
kit according to the manufacturer’s protocol.
TNBC-secreted exosomes were further confirmed using
transmission electron microscopy (TEM). Exosomes were fixed
with 1% glutaraldehyde in 1× PBS for 10 min, and then the fixed
sample was loaded on a carbon/formvar coated grid and dried on
filter paper under vacuum for 20 min. The grids were washed with
distilled water and negatively stained with 2% aqueous uranyl
acetate for 30 s. Grids were air dried and then examined using
TEM (FEI Tecnai G2 F20 S-TWIN FEGTEM).
Cell Viability Assay
MDA-MB-231 cells (5 × 103 cells/well) were plated in 96-
well culture plates and incubated overnight at 37◦C. The
cells were treated with exosomes originating from vehicle− or
compound−treated cells (0.5% DMSO, 11 µM DET, or 3 µM
DETD-35) for 24 h. Cell growth was examined using MTT-based
colorimetric assay as previously described (Chiang et al., 2005).
Measurement of Mitochondrial
Membrane Potential
Breast cancer cells (1.5 × 105 cells/well) were seeded in 6-well
culture plates overnight and treated with vehicle (DMSO, 0.5%),
DET (11 µM), or DETD-35 (3 µM) for 2 h at 37◦C. Then, 5 µL
of 10 µM DiIC1(5) fluorescence dye was added into the treated
cells and incubated for 30 min at 37◦C. After washing cells with
PBS, the mitochondrial membrane potential of treated cells was
determined by flow cytometry.
Determination of Intracellular Calcium
Concentration
MDA-MB-231 cells (1.5 × 105 cells/well) were grown in 6-well
culture plates and incubated overnight to allow cell adhesion. The
cells were treated with vehicle (DMSO, 0.5%), DET (11 µM),
or DETD-35 (3 µM) for 2 h. Cells were washed with Hank’s
buffered salt solution (HBSS) (Gibco) and then incubated in
HBSS containing 2 µM Fluo-4 AM calcium indicator at 37◦C
for 30 min. The vehicle− or compound−treated cells were
washed with HBSS and the positive control group consisted of
cells treated with HBSS containing 4 µM ionomycin, a Ca2+
ionophore, for 5 min. Flow cytometry was used to measure the
change of Fluo-4 AM fluorescence intensity in the treated cells.
Protein Digestion and iTRAQ Labeling
Exosome pellets from vehicle− or compound−treated cells were
lysed with 8 M urea in 50 mM Tris buffer (pH 8.5). Protein
concentration was measured by Pierce 660 nm protein assay
(Thermo Scientific, Rockford, IL, United StatesA) according to
the manufacturer’s protocol. Twenty-five micrograms of exosome
samples were reduced with 10 mM DL-dithiothreitol (DTT)
in 8 M urea in 50 mM Tris buffer (pH 8.5) at 37◦C for
1 h and subsequently alkylated with 50 mM iodoacetamide
(IAA) in 8 M urea in 50 mM Tris buffer (pH 8.5) at room
temperature (RT) for 30 min in the dark. The reaction was
stopped with 100 mM DTT in 8 M urea in 50 mM Tris
buffer (pH 8.5), and the urea was diluted to a concentration
of 4 M urea with 50 mM Tris buffer (pH 8.5). The Lys-
C protease (1:200) (Wako) was added and incubated at RT
for 4 h. Finally, the solution was diluted to 0.8 M urea
concentration with 50 mM Tris buffer (pH 8.0), and then
trypsin (1:50) (Promega) was added and the solution was
incubated overnight at 37◦C. An Oasis HLB column (Waters
Corporation) was employed to remove detergents or salts from
the solution of digested proteins and dried in a SpeedVac.
Each digested sample was labeled with 4-plex iTRAQ reagent
(AB SCIEX, Foster City, CA, United States) according to the
manufacturer’s protocol. Specific labeling was performed as 114,
115, and 116 isobaric tag 4-plex iTRAQ reagents for vehicle
control, DET, and DETD-35 exosomal samples, respectively.
Three iTRAQ-labeled exosomal samples were combined and
dried using a SpeedVac.
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Strong Cation Exchange Fractionation
and LC-MS/MS Analysis
The combined samples were resuspended in 10 mM KH2PO4,
pH 2.65, 25% acetonitrile (Buffer A) and then loaded into
the Strong Cation Exchange (SCX) column (Polysulfoethyl A,
4.6 × 200 mm, 5 µm polysulfoethyl aspartamide beads, 300 Å
pore size) (Poly LC Inc.) at a flow rate of 1 ml/min. The
gradient was started with 0% Buffer B (1 M KCl in Buffer
A, pH 2.65), then increased to 15% Buffer B at 20 min,
to 30% Buffer B for 10 min, to 50% Buffer B for 5 min
and held at 50% Buffer B for 5 min, and finally 1 min to
100% Buffer B. The fraction was collected every 30 sec, and
subsequently desalted with Oasis HLB column and dried using
a SpeedVac.
The LC-nESI-Q Exactive mass spectrometer model from
Thermo Fisher Scientific coupled with an on-line nanoUHPLC
(Dionex UltiMate 3000 Binary RSLCnano) was used for protein
identification and analysis. An Acclaim PepMap 100 C18 trap
column (75 µm × 2.0 cm, 3 µm, 100 Å, Thermo Fisher
Scientific) and an Acclaim PepMap RSLC C18 nano LC column
(75 µm × 15 cm, 2 µm, 100 Å) were utilized to deliver solvent
and separate tryptic peptides with a linear gradient from 3 to
30% of acetonitrile in 0.1% (v/v) formic acid for 3 h at flow rate
of 300 nL/min. The acquisition of the MS data was performed
in data dependent mode with a full MS scan followed by 10
MS/MS scans of the top 10 precursor ions from the MS scan.
The MS scan was performed with a resolving power of 70,000
over the mass-to-charge (m/z) range 380 to 1800 and dynamic
exclusion enabled. The data dependent MS/MS acquisitions were
performed with: 2 m/z isolation window, 27 NCE, and 17,500
resolving power.
Protein Identification and Quantitation
Peptide and protein identification was performed using the
Proteome Discoverer software (v.1.4.1.14., Thermo Fisher
Scientific) with SEQUEST and MASCOT search algorithms
(Matrix Science) against a Swiss-Prot human protein database
of Human uniprot 148,986 entries. The parameters for database
searches were set as follows: full trypsin digestion with two
maximum missed cleavage sites, precursor mass tolerance
of 10 ppm, fragment mass tolerance of 0.02 Da, dynamic
modifications of oxidation at methionine (M) residues, and
static modifications of carbamidomethylation at cysteine (C)
residues, iTRAQ 4plex at lysine residues and N-terminal
proteolytic peptides. The identified peptides were validated using
Percolator algorithm against the decoy database search which
rescored peptide spectrum matches (PSM) by q-values and
posterior error probabilities. All the peptides were filtered with
a q-value threshold of 1% false discovery rate (FDR), with the
identified protein having a minimum of two unique peptides.
For quantitative analysis, the relative abundance of each protein
present in two biological replicates was calculated based on the
iTRAQ reporter ion ratios of 115/114 and 116/114 found at the
peptide level. The Z-score cutoff of ±1.96σ (representing 95%
confidence level) was set as a threshold for defining differentially
expressed proteins (Berard et al., 2012).
Bioinformatics Analysis
Molecular functions of the differentially expressed proteins from
both compound treatments relative to vehicle control were
analyzed on the Gene Ontology (GO) search through Proteome
Discoverer application to ProteinCenter database. GO biological
process annotation of the up- and down-regulated proteome
observed in compound treatment was carried out using DAVID
bioinformatic Resources 6.8. The significantly enriched biological
processes of the up- and down-regulated protein expressions
in the exosomal proteome were picked out, and the threshold
of statistical significance was set as the –log(p-value) value of
1.3 (P < 0.05). The Ingenuity Pathway Analysis (IPA) database
search tool (Ingenuity Systems) was used to further analyze the
differentially expressed proteins responsive to both compound
treatments involved in biological mechanisms that relate to
canonical pathways and toxicity. The −log(p-value) of 1.3 was
considered statistically significant in the canonical pathway and
toxicity list analysis of IPA.
Western Blot Analysis
The collected TNBC cells were subjected to lysis by
radio-immunoprecipitation assay (RIPA) lysis buffer (Santa
Cruz Biotechnology, United States). Protein concentration
was measured by Pierce 660 nm protein assay (Thermo
Scientific, Rockford, IL, United States) according to the
manufacturer’s protocol. Protein samples were separated by 10
or 12.5% SDS-PAGE, and subjected to transblotting analysis
according to a method published elsewhere (Lee et al., 2010).
Enhanced chemiluminescent detection reagents (Amersham;
Thermo Scientific) were employed to visualize the reactive
protein bands by exposure to chemiluminescence light film
(BioMax; Kodak Co.). Quantification of the reactive protein
band expression used ImageJ software.
Immunofluorescence Cell Staining
MDA-MB-231 cells (2× 104 cells/well) were seeded on glass slips
in 24-well culture plates overnight, and then treated with vehicle
(DMSO, 0.5%), DET (11 µM), or DETD-35 (3 µM) for 24 h. The
fix and block steps of treated cells followed the method previously
described (Lee and Shyur, 2012). After washing with PBS, cells
on glass slips were incubated with primary antibody VDAC1
in blocking buffer (1:100) at 4◦C for 18 h, and then washed
and stained with FITC conjugated secondary antibody (1:200) at
RT for 3 h (Jackson ImmunoResearch Laboratories). The nuclei
region of treated cells was stained with DAPI (Sigma–Aldrich),
and the cells were mounted onto a glass slide with Gold Antifade
Reagent (ProLong). The Zeiss LSM 780 plus Elyra confocal
microscope was used to visualize and capture the stained cells.
Transmission Electron Microscopy
MDA-MB-231 cells were prefixed with 0.1 M cacodylate buffer
containing 2.5% glutaraldehyde and 0.1% tannic acid for 30 min
at RT, and washed with PBS. Post-fixing was carried out using 1%
osmium tetroxide in 0.1 M cacodylate buffer at RT for 30 min, and
then washed and dehydrated through a graded series (30–100%)
of ethanol. The cells were embedded in Spurr’s resin (EMS),
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and polymerized at 70◦C for 48 h. The polymerized samples
were sectioned and stained with uranyl acetate and lead citrate,
and then visualized by electron microscopy (FEI Tecnai G2 F20
S-TWIN FEGTEM).
Statistical Analysis
All data are presented as means ± standard deviation (SD).
Statistical analysis of experimental results was carried out using
the SAS program (SAS Institute), and significant differences
between different treatment groups were examined using
ANOVA. P-values of less than 0.05 were regarded as a statistically
significant.
RESULTS
DET and DETD-35 Caused Structural
Damage and Dysfunction of
Mitochondria in MDA-MB-231 Cells
According to our previous investigation, DETD-35 has a more
potent anti-proliferative effect than the parental DET, showing
an approximate 3.5-fold decrease (11 µM vs. 3 µM) in IC50
value in the human TNBC cell line, MDA-MB-231 (Shiau et al.,
2017). In this study, we treated TNBC cells with the IC50
concentration of DET (11 µM) and DETD-35 (3 µM) for
24 h and examined the phenotypic changes using TEM. As
shown in Figure 1A, the intact rough endoplasmic reticulum
(RER) structures made by the ribosomes decorating the RER
membrane were only seen in the vehicle−treated cells, and were
not observed treatment with either compound. Both compounds
significantly induced massive cytoplasmic vacuole (asterisks)
formation in MDA-MB-231 cells. The structural integrity of
mitochondria (mt) was also damaged in compound−treated cells
compared to the vehicle control. We further evaluated whether
both DET− and DETD-35−induced morphological damage in
mitochondria caused mitochondrial dysfunction in the treated
TNBC cells. The status of the mitochondrial membrane potential
was first determined using MitoProbe DiIC1(5) fluorescent dye in
the TNBC cells treated for 2 h. A loss of mitochondrial membrane
potential in cells by either DET (27%) or DETD-35 (23.5%)
treatment relative to vehicle−treated cells (100%) was indeed
observed (Figure 1B). Of note, at 12 h treatment with DET,
protein expression level of voltage-dependent anion channel 1
(VDAC1), a mitochondrial metabolite transporter critical in the
activation of the mitochondria-mediated apoptotic process had
increased about 2-fold; DETD-35 treatment for the same time
period induced a 1.67-fold increase, both relative to the vehicle
control (Figure 1C). Confocal microscopy was further used to
examine the immunofluorescence staining of VDAC1 in the 24-h
treated MDA-MB-231 cells. Positive staining of VDAC1 protein
(green) was observed mainly distributed in the cytoplasm of
vehicle−treated cells; however, in DET− and DETD-35−treated
cells, the VDAC1 protein appeared at the membrane surrounding
the expanded vacuoles in the cytosol or accumulated in the
perinuclear region and less VDAC1 expression was also observed
in DETD-35−treated cells (Figure 1D). The data suggest
that both DET− and DETD-35−induced vacuole formation
might be in part derived from mitochondria that might cause
mitochondrial dysfunction in the human TNBC cells.
DET and DETD-35 Increased Cytosolic
Calcium Concentration in TNBC Cells
Deregulation of intracellular calcium homeostasis is known to
be one of the features of mitochondrial dysfunction in cells
(Boland et al., 2013). Next, we examined whether both DET and
DETD-35 treatment can interfere with intracellular calcium level
in TNBC cells. The calcium (Ca2+) sensitive fluorescent dye,
Fluo-4 acetoxymethyl (AM) and flow cytometry were employed
to analyze vehicle− or compound−treated MDA-MB-231 cells
to detect the change of cytosolic free Ca2+ level. The result,
shown in Figure 2A, shows that the mean intensity of
Fluo-4 dye in DET− and DETD-35−treated TNBC cells was
significantly induced 2.4- and 2.0-fold, respectively, compared
to vehicle−treated cells. The increase in Fluo-4 fluorescence
intensity (∼1.8-fold) was also observed in the cancer cells treated
with calcium ionophore ionomycin, used as a positive control
in this experiment. On the other hand, pretreatment for 30 min
with 20 µM calcium chelator, 1,2-bis(2-aminophenoxy)ethane-
N,N,N′,N′-tetraacetic acid tetrakis (BAPTA-AM), before either
DET or DETD-35 treatment effectively diminished the increase
of Fluo-4 fluorescence intensity in compound−treated cells
and the Ca2+ levels were similar to the vehicle−treated
cells (Figure 2B). These data indicate that both compounds
significantly promoted intracellular Ca2+ content, which may be
because of their damaging effect on calcium storage organelles,
such as the mitochondria and endoplasmic reticulum (ER) in the
TNBC cells.
DET and DETD-35 Promoted
Ca2+-Dependent Release of Exosomes
from TNBC Cells
Several articles have reported that the increase in intracellular
calcium level in mammalian cells is positively correlated to the
release of cell-derived exosomes (Savina et al., 2003; Urbanelli
et al., 2013). We thus further evaluated whether DET or
DETD-35 treatment can affect exosome release in TNBC cells
using a differential ultracentrifugation approach adapted from
a published protocol with some modifications (Théry et al.,
2006) (Figure 3A). The quality of collected exosomes from
the culture medium of TNBC cells was examined using TEM
and immunoblotting of exosomal marker proteins, including
TSG101 and CD9. As shown in Figure 3B, the diameter range of
TNBC cell-secreted exosomes was between 50 and 100 nm which
perfectly matched with typical exosome size range (40–100 nm
diameter) (Simons and Raposo, 2009). The western blotting data
showed that tumor susceptibility gene 101 protein (TSG101), a
commonly used exosomal marker protein was indeed detected in
the exosomes. A significant amount of TSG101 was also detected
in the cytosolic protein fraction, as this protein is also a member
of endosomal sorting complex required for transport (ESCRT)
complex involved in the biogenesis of multivesicular bodies
(MVBs) in the cells (Urbanelli et al., 2013). The representative
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FIGURE 1 | Deoxyelephantopin (DET) and DET derivative (DETD)-35 induced morphological change and challenged structural integrity of mitochondria in
MDA-MB-231 cells. (A) MDA-MB-231 cells were treated with vehicle (0.5% DMSO) or IC50 concentrations for inhibiting MDA-MB-231 cells of DET (11 µM) and
DETD-35 (3 µM) for 24 h, and the morphological changes of cancer cells were examined by transmission electron microscopy (TEM) imaging (10,000×
magnification). The ER, mitochondria (mt), and cytoplasmic vacuoles are indicated by black arrowheads, white arrowheads, and asterisks, respectively.
(B) MDA-MB-231 cells were treated with vehicle (0.5% DMSO), 11 µM DET, and 3 µM DETD-35 for 2 h. The vehicle– and compound–treated cells were labeled with
DiIC1(5) (10 µM) fluorescence dye for 30 min, and mitochondrial membrane potential of the treated cells was determined using flow cytometry. Data are
mean ± SEM, n = 3. Different letters indicate significant differences (one-way ANOVA, P < 0.05). (C) Western blotting of VDAC1 protein in MDA-MB-231 cells
treated with vehicle (0.5% DMSO), 11 µM DET, or 3 µM DETD-35 for 4, 8, and 12 h. Quantification of the corresponding protein bands was performed using ImageJ
software. β-actin was used as a loading control. (D) Immunofluorescence analysis of MDA-MB-231 cells treated with vehicle (0.5% DMSO), DET (11 µM), or
DETD-35 (3 µM) for 24 h. The treated cells were fixed using 100% ice-cold methanol, and stained with VDAC1 (green), and DAPI (blue) to visualize mitochondrial
structures and nuclei. White arrowheads indicate DET– and DETD-35–induced cytoplasmic vacuoles.
exosomal marker protein CD9 was detected at the highest
level in the TNBC cell-derived exosomes, while GAPDH, an
abundant cytoplasmic protein, was only found in TNBC cell
protein lysates, indicating high purity of collected exosomes
secreted from TNBC cells. Next, we examined whether both
DET and DETD-35 treatments influence the exosome release
in MDA-MB-231 cells. Several batches of TNBC cell-derived
exosomes were collected after treatment with vehicle control,
DET (11 µM), and DETD-35 (3 µM) at the indicated times, and
the total exosomal proteins were extracted and measured for the
enzymatic activity of acetylcholinesterase (AChE), an exosomal
marker protein. Surprisingly, both DET and DETD-35 treatment
enhanced exosome release into the culture medium with the most
significant induction revealed at the 8 h treatment compared
to vehicle−treated cells (Figure 4A). The cell populations were
similar in vehicle− or compound−treated cells. In view of
such important phenomena being observed by DET/DETD-35
treatment, we further examined whether it was through Ca2+-
dependent pathway. We designed a calcium chelator BAPTA-AM
pretreatment experiment (for 30 min) prior to compound
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FIGURE 2 | Deoxyelephantopin and DETD-35 induced the calcium ion levels in TNBC cells. (A) MDA-MB-231 cells were treated with vehicle (0.5% DMSO), DET
(11 µM), or DETD-35 (3 µM) for 2 h. In parallel, TNBC cells were treated with ionomycin (4 µM) for 5 min as a positive control. Cytosolic free calcium level was
determined with Fluo-4 Ca2+ fluorescent dye in the treated cells using flow cytometry. (B) MDA-MB-231 cells were pre-treated with 20 µM calcium chelator
BAPTA-AM for 30 min, and then treated with vehicle or both compounds for 2 h. Detection of cytosolic free calcium level in the treated cells used flow cytometry.
FIGURE 3 | Characterization of the quality of MDA-MB-231 cell-derived exosomes. (A) Flow chart of cell-derived exosome isolation and purification from culture
medium by differential centrifugation. (B) Purified exosomes from the 24-h vehicle–treated TNBC cells were examined using transmission electron microscopy (TEM)
imaging (9,900× and 19,500× magnification). Immunoblotting of exosomal marker proteins, TSG101 and CD9, from the same batch of exosomes. GAPDH was
used as a positive control of cytosolic proteins.
treatment (for 8 h) and quantified the released exosome amounts
by measuring AChE activity. BAPTA-AM significantly prevented
exosome release in the DET−treated cells (P < 0.05), and
the Ca2+ chelator partially inhibited the effect of DETD-35
on exosome release (P < 0.066) (Figure 4B). These results
indicated that exosome secretion stimulated by either compound
is involved in the calcium-dependent mechanism. The role of
exosomes in affecting the recipient or neighboring cell activity
has been reported (O’Brien et al., 2013; Harris et al., 2015). We
further investigated whether the secreted exosomes isolated from
DET− or DETD-35−treated cancer cells may have an effect on
TNBC cell activity, as a recipient. We collected the TNBC cell-
derived exosomes with the highest secretion at 8 h vehicle or
compound treatment, and added 3.6 and 7.2 µg/mL exosomes,
respectively, to a culture medium of fresh MDA-MB-231 cells
and incubated for 24 h. The TNBC cell viability was then
evaluated by MTT assay. Strikingly, the exosomes secreted
from the parental TNBC cells treated with DET or DETD-35
significantly inhibited the viability of recipient MDA-MB-231
cells dose-dependently compared to the exosomes collected
from vehicle control cells (Figure 4C). The DETD-35−induced
released exosomes showed more MDA-MB-231 cell proliferation
inhibition activity than DET−induced exosomes (21–29% vs.
15–22% inhibition) (P < 0.05) in a dose-dependent manner.
Together, these results indicate that both DET and DETD-35
promoted release of exosomes from TNBC cells is directly
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correlated to their effect on increasing intracellular Ca2+ levels
in the cancer cells.
Comparative Exosomal Proteomes
Analysis
Next, we used a mass spectrometry (MS)-based quantitative
proteomics approach coupled with Ingenuity Pathway Analysis
(IPA) database analysis to investigate whether the exosomes
produced from compound−treated cells act as a deregulator
against TNBC cell activity by changing their vesicle protein
content or function. The differentially expressed exosomal
proteins responsive to DET or DETD-35 treatment were
analyzed at 8 h by isobaric tags for relative and absolute
quantitation (iTRAQ)-based comparative exosomal proteomics.
Based on at least two unique peptides and 1% FDR, we
quantitatively identified a total of 2243 and 2626 proteins,
respectively, in two biological replicates (Supplementary
Tables S1, S2). Among them, 1768 proteins were commonly
present in these two biological replicates (Figure 5A and
Supplementary Table S3). The differentially expressed proteins
in both compound treatments relative to vehicle control were
selected based on Z-score cutoff of ±1.96σ (representing
95% confidence level) (Berard et al., 2012). The significantly
up- and down-regulated exosomal proteins responsive to
compound treatment were calculated and determined as 67
and 27 proteins for DET, and 71 and 28 proteins for DETD-35,
respectively (Supplementary Tables S4, S5). Furthermore, the
molecular functions of up- and down-regulated exosomal
proteins observed in both compound treatments were identified
based on a GO search. The significantly expressed exosomal
proteins were mostly classified into the protein binding,
structural molecule activity, catalytic activity, and metal ion
binding categories (Figure 5B). The GO biological process
annotation of the compound-responsive exosomal proteome
was performed by the “database for annotation, visualization
and integrated discovery” (DAVID) bioinformatic tool. All
compound-responsive exosomal proteins were further classified
into groups based on similar annotation terms describing
the biological processes. The significant biological process
of each group was picked out based on −log(p-value) of
1.3 (representing P < 0.05) as the threshold for statistical
significance. As shown in Figure 5C, the top 6 significantly
enriched biological processes of the up-regulated exosomal
proteins responsive to DET or DETD-35 treatments were
similar, such as SRP-dependent cotranslational protein targeting
to membrane, viral transcription, nuclear-transcribed mRNA
catabolic process, translational initiation, rRNA processing,
and translation. However, unique biological processes of
exosomal proteins were also seen in the two treatment groups.
Nucleosome assembly, maturation of small subunit ribosomal
RNA (SSU-rRNA) from tricistronic rRNA transcript, ribosomal
small subunit biogenesis, and liver regeneration were specific to
DET treatment, and coding region determinant (CRD)-mediated
mRNA stabilization, cytoplasmic translation, ribosomal large
subunit assembly, and mRNA splicing via spliceosome were
specific to DETD-35 treatment. Conversely, the top 10
FIGURE 4 | Deoxyelephantopin and DETD-35 promoted a time-dependent
release of TNBC cell-derived exosomes. (A) MDA-MB-231 cells were treated
with vehicle (0.5% DMSO), DET (11 µM), and DETD-35 (3 µM) at the
indicated time periods (4, 8, and 12 h), and then the TNBC-secreted
exosomes were collected from culture media using differential centrifugation.
The activity of acetylcholinesterase (AChE), an exosome marker protein, was
determined using fluorescence microplate reader. Data are mean ± SEM,
n = 3. (B) MDA-MB-231 cells were pre-treated with 20 µM calcium chelator
BAPTA-AM for 30 min, and then treated with either vehicle, DET or DETD-35
for 8 h. The release of treated cell-derived exosomes was separated by
differential centrifugation. Data are mean ± SEM, n = 3. (C) The exosomes
(3.6 and 7.2 µg/mL, respectively) collected from the culture medium of
vehicle–, DET–, or DETD-35–treated cells) were added into the freshly cultured
MDA-MB-231 cells for 24 h, and the TNBC cell viability was determined using
MTT assay. Different letters indicate significant differences (one-way ANOVA,
P < 0.05). The difference of DETD-35–treated cells with or without
BAPTA-AM pretreatment presented in (B) was further analyzed by student
t-test and labeled with asterisk.
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FIGURE 5 | Comparison of exosomal proteome originated from DET– and DETD-35–treated MDA-MB-231 cells. (A) Venn diagram showing the overlapping and
unique exosomal proteins between the two biological replicates in DET– or ETD-35–treated TNBC cells. (B) Molecular functions of significantly expressed
compound-responsive exosomal proteins were classified based on the gene ontology (GO) categorization. (C) The significantly differential expression of exosomal
proteins responsive to both compound treatments were clustered into groups according to the GO biological processes terms by DAVID Bioinformatics tools. The
top 10 significantly enriched biological processes of the up- and down-regulated protein expressions in the exosomal proteome were selected out, and ranked on the
basis of based on –log(p-value) value high than 1.3 (P < 0.05). The black dotted line indicates –log(p-value) value of 1.3 as the threshold for statistical significance.
enriched biological processes of down-regulated exosomal
proteins responsive to both compounds were quite focused
on cell migration, basement membrane (BM) organization,
collagen-activated tyrosine kinase receptor signaling pathway,
collagen fibril organization, angiogenesis, extracellular matrix
disassembly and organization, collagen catabolic process, and
cell adhesion. Specifically, the protein expression of laminin
subunit alpha-5 and subunit gamma-1, collagen alpha-1(V)
chain involved in cell migration, collagen alpha-2(IV) chain,
collagen alpha-1(XVIII) chain, lactadherin, and BM-specific
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heparin sulfate proteoglycan core protein for angiogenesis, and
tubulointerstitial nephritis antigen-like, collagen alpha-1(XII)
chain, lysyl oxidase homolog 2, epidermal growth factor
(EGF)-like repeat and discoidin I-like domain-containing
protein 3, and laminin subunit alpha-2 for cell adhesion activity
were attenuated.
Analysis of Differentially Expressed
Proteins in Exosomes
Next, the IPA database was employed to analyze the differentially
expressed exosomal proteins involved in biological mechanisms
that relate to canonical pathways and toxicity with the
−log(p-value) of 1.3 (P < 0.05) set out as statistical significance.
We observed that several exosomal proteins responsive to DET
and DETD-35 treatment are commonly involved in mediation
or regulation of eukaryotic initiation factor 2 (EIF2) signaling,
eukaryotic initiation factor 4 (eIF4) and p70S6K signaling,
mechanistic target of rapamycin (mTOR) signaling, hepatic
fibrosis/hepatic stellate cell activation, γ-glutamyl cycle, and
glutathione biosynthesis (Figure 6A). Nevertheless, specific
canonical pathways unique to either compound were also found,
for example, adenine and adenosine salvage VI and spermidine
biosynthesis I specific for DET treatment, and role of interleukin
17A (IL-17A) in psoriasis, liver X receptor/retinoid X receptor
(LXR/RXR) activation, and calcium transport I specific for
DETD-35 treatment (Figure 6A). In the IPA toxicity list analysis,
hepatic fibrosis, recovery from ischemic acute renal failure,
and acute renal failure panel were significantly observed for
both compound treatments (Figure 6B). Furthermore, DETD-35
responsive exosomal proteome was also implicated in some of the
biological mechanisms related to toxicity such as oxidative stress,
positive acute phase response proteins, LXR/RXR activation,
increase liver hepatitis, renal necrosis/cell death, and primary
glomerulonephritis biomarker panel (P < 0.05) (Figure 6B and
Supplementary Tables S6, S7). Although these toxicity functions
were also observed for DETD-35, in the toxicity list result of
DET responsive exosomal proteome, the P-value was higher than
0.05 (P = 0.09–0.21). Together, the particular toxicity functions,
(i.e., decrease of transmembrane potential of mitochondria
and oxidative stress) observed in the proteomics study, lend
strong support to the DET−/DETD-35−induced mitochondrial
dysfunction characterized in this study, and the ROS-mediated
cytotoxicity and programmed cell death against breast cancer
cells or melanoma cells induced by DET/DETD-35 reported in
our previous studies (Lee and Shyur, 2012; Feng et al., 2016;
Nakagawa-Goto et al., 2016).
ROS Plays a Role in DET/DETD-35
Regulated Exosome Release and
Anti-TNBC Cell Proliferation
To further evaluate whether the ROS induced by either
compound affects mitochondrial structures or functions,
and/or TNBC cell-secreted exosome amounts, we used ROS
scavenger, N-acetylcysteine (NAC) pretreatment for 1 h before
either DET or DETD-35 treatment and then examined the
mitochondrial structures by VDAC1 staining and confocal
FIGURE 6 | Canonical pathways and toxicity lists of differentially expressed compound-responsive exosomal proteins generated by IPA database analysis. The
significant canonical pathways (A) and toxicological events (B) of the differentially expressed exosomal proteins responsive to both compound treatments were
performed using IPA database analysis. The –log(p-value) of 1.3 (P < 0.05) was considered as statistical significance in IPA analysis. The black dotted line indicates
–log(p-value) value of 1.3 as the threshold.
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FIGURE 7 | Pretreatment with ROS scavenger NAC prevents DET and DETD-35 induced mitochondrial dysfunction and reverted exosome release from cancer cells
and their cytotoxic activity. (A) Immunofluorescence confocal micrographs of MDA-MB-231 cells pre-treated with 5 mM NAC for 1 h, and then treated with the
vehicle (0.5% DMSO), 11 µM DET and 3 µM DETD-35 for 24 h. The treated cells were fixed using 100% ice-cold methanol, and stained with VDAC1 (green) and
DAPI (blue) to visualize mitochondrial structures and nuclei. Immunoblotting of VDAC1 protein in the TNBC cells were pre-treated with 5 mM NAC for 1 h, and then
treated with vehicle or compounds for 12 h. β-actin was used as a loading control. (B) MDA-MB-231 cells were pre-treated with 5 mM NAC for 1 h, and then treated
with vehicle or either compound at the same concentration for 2 h. Cytosolic free calcium level in cancer cells was determined using Fluo-4 Ca2+ fluorescent dye
using flow cytometry. (C) TNBC cells were pre-treated with 5 mM NAC for 1 h, and then treated with vehicle or either compound for 4 h and 8 h, and then the TNBC
cell-secreted exosomes were collected from the culture media using differential centrifugation. Exosome samples were prepared by using a working solution
containing PBS, RIPA buffer and protease inhibitors. The activity of acetylcholinesterase (AChE) was determined using fluorescence microplate reader. Data are
mean ± SEM, n = 3. (D) Exosomes were isolated from TNBC cells pre-treated with NAC (5 mM) for 1 h, then treated with vehicle or either compound for 8 h; the
culture media were collected to purify the exosomes. The purified exosomes (3.6 and 7.2 µg/mL, respectively) were added into the fresh-cultured MDA-MB-231
cells for 24 h, and the TNBC cell viability was determined using MTT assay. Different letters indicate significant differences (one-way ANOVA, P < 0.05). (E) The
proteins isolated from exosomes prepared with the procedure described in (D) were subjected to immunoblotting of HSP27 and exosomal marker TSG101.
microscopy, and intracellular Ca2+ levels by Fluo-4 AM
dye staining. Mitochondria-derived cytoplasmic vacuolation,
up-regulated expression of VDAC1 protein (Figure 7A), and
increased level of cytosolic free Ca2+ ions induced by both
compound treatments (Figure 7B) were significantly attenuated
by pretreatment with NAC. In addition, NAC pretreatment
could also significantly reverse both compound-induced
time-dependent release of exosomes from TNBC cells into
culture media (Figure 7C); notably, the anti-proliferative
activity of DET− and DETD-35−induced exosomes were
abolished (Figure 7D). We have previously found that both
DET and/or DETD-35 could significantly induce the generation
Frontiers in Pharmacology | www.frontiersin.org 11 June 2017 | Volume 8 | Article 398
fphar-08-00398 June 29, 2017 Time: 10:41 # 12
Shiau et al. Phyto-Sesquiterpene Lactone Regulates Exosomal Activities
of ROS in TS/A(ER+) mammary cancer cells, MDA-MB-231
cells or human BRAF mutant A375 melanoma cells (Lee
and Shyur, 2012; Feng et al., 2016; Shiau et al., 2017). In the
data about the exosomal proteome and the IPA toxicity list
analysis, heat shock protein beta-1 (HSPB1), a member of the
small heat shock protein (sHSP) family, also known as heat
shock protein 27 (HSP27), and collagen alpha-2(IV) chain
(COL4A2), a BM-related protein, were found correlated to the
toxicity function of decrease of transmembrane potential of
mitochondria. We further validated these results by western
blotting, and observed that up-regulation of HSPB1 in compound
responsive exosomes was significantly reduced by implementing
NAC pretreatment (Figure 7E), suggesting that generation
of ROS indeed plays a pivotal role as an upstream initiator
to facilitate the cytotoxic effects of both DET and DETD-35
against TNBC cell activity by manipulating exosomal protein
content and activity. Together, these results indicate that
DET− or DETD-35−induced ROS is a crucial factor affecting
the release and activity of secreted forms of exosomes from
cancer cells and damaging the Ca2+ storage organelles, like
mitochondria, in TNBC cells attributed to their anti-cancer
effects.
DISCUSSION
A growing body of evidence indicates that exosomes mediate
the delivery of proteins, mRNAs, and miRNAs from cancer cells
to recipient or neighboring cells by cell-to-cell communication,
which may assist in the creation of a metastatic niche and
facilitate cancer cell progression and metastasis, or influence the
activity and/or behaviors of recipient cells (O’Brien et al., 2013;
Costa-Silva et al., 2015). Ca2+ ions are known to participate
in the earlier stages of MVB biogenesis and the membrane
fusion events regulating the secretion mechanism of exosomes
(Savina et al., 2005; Urbanelli et al., 2013). In this study, we
observed that the germacranolide sesquiterpene lactone DET
and its derivative DETD-35 significantly induced the release
of exosomes from MDA-MB-231 cells into media compared to
the vehicle−treated cells, and a significant secretion flux was
observed at 8-h treatment. The increase of exosome secretion
in TNBC cells stimulated by DET or DETD-35 is likely
the downstream cascade event after the compounds induce
a significant amount of free Ca2+ ions in cell cytoplasm
(observed within 2 h), because calcium chelator BAPTA-
AM pretreatment significantly blockaded the ability of DET
or DETD-35 to stimulate cancer cell release of exosomes.
These results suggest the mechanisms by which DET and
DETD-35 facilitate Ca2+-dependent exosome release from
cancer cells.
The ER and mitochondria are two major calcium storage
organelles. They might play a cooperative partnership role
to maintain the balance of intracellular Ca2+ concentration
when xenobiotic stimulation causes the release of ER Ca2+
into the cytosol through ER calcium-release channels (Mizuno
et al., 2013). On the other hand, the mitochondria rapidly take
up the increased cytosolic free Ca2+ by the mitochondrial
metabolite transporter VDAC at the outer mitochondrial
membrane and the mitochondrial calcium uniporter (MCU)
at the inner mitochondrial membrane (Boland et al., 2013).
Very recently, we have demonstrated that both DET and
DETD-35 can significantly induce the formation of ER-
derived cytoplasmic vacuoles resulting in paraptosis-like cell
death in MDA-MB-231 cells within 24 h of treatment (Shiau
et al., 2017). Here, we observed that shorter (2 h) and longer
(24 h) treatment with both compounds could induce different
degrees of mitochondria structural or functional damage in
the TNBC cells, such as the loss of mitochondrial membrane
potential within 2 h, over-regulated VDAC1 expression
between 8 and 12 h, and formation of mitochondria-derived
cytoplasmic vacuoles within 24 h (Figure 1). The results indicate
that DET and DETD-35, aside from inducing ER damage,
also elicited mitochondrial dysfunction in MDA-MB-231
cells. The mitochondrial dysfunction under chemical agent
stimulation could be the result of changed mitochondrial
permeability transition (MPT), increased ROS generation,
damaged mitochondrial DNA (mtDNA) and mitochondrial
respiration, and suppression of fatty acid oxidation (Vuda and
Kamath, 2016). Besides, high concentrations of cytosolic Ca2+
and ROS are considered to be the regulators that enhance
the opening of MPT pores (Nadanaciva and Will, 2009). We
observed previously that DET induced ROS production within
2 h and facilitated ROS-associated ER stress in TS/A(ER+)
mammary cancer cells (Lee and Shyur, 2012). In this and
our previous studies (Shiau et al., 2017), we also detected
DET− and DETD-35−induced ROS production within
2 h in MDA-MB-231 cells that we believe are associated
with ROS-mediated ER stress probably including MPT
pore opening, and subsequently promoting the release of
ER or mitochondrial Ca2+ into the cytoplasm resulting in
the enhancement of exosome secretion from the treated
TNBC cells. Notably, all of the observed biological events
triggered by DET/DETD-35 treatment in cancer cells can
be reverted by pretreatment with ROS scavenger NAC,
demonstrating that ROS induced by either compound
plays a key role in their suppressive effects against TNBC
cells.
Oxidative stress is known to regulate exosome secretion
and their constituents. For example, oxidative stress influences
exosomal mRNA composition that may protect recipient
cells by strengthening their tolerance to oxidative stress and
subsequent cell death (Eldh et al., 2010). In this study, we
surprisingly observed that the exosomes collected from DET−
and DETD-35−treated MDA-MB-231 cells have the ability
to inhibit the same cancer cell proliferation. The yield of
exosomes collected from ROS scavenger NAC plus DET or
DETD-35 treated cells was significantly reduced, and the
exosomes no longer showed anti-cancer cell activity. These
data suggest oxidative stress induced by either compound
might de-regulate exosome biogenesis and also their constituent
compositions. By using a comparative MS-based quantitative
proteomics approach coupled with Ingenuity Pathway Analysis
(IPA) database analysis, we found that expression levels of
BM-related proteins, such as laminin subunits alpha-2, alpha-5,
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and gamma-1, collagen alpha-1(V) chain, alpha-1(XII) chain,
alpha-1(XVIII) chain, and alpha-2(IV) chain, and BM-specific
heparin sulfate proteoglycan core protein, were down-regulated
in TNBC cell-derived exosomes by either compound treatment.
These proteins were reported to be involved in cancer cell
adhesion, migration, proliferation, and differentiation, and affect
tumor progression (Patarroyo et al., 2002). For example, laminin
subunit alpha-5 fragments were able to bind with αvβ3 integrin
to promote angiogenesis of endothelial cells (Gopal et al., 2016),
and laminin-5 could interact with its receptor α6β4 integrin to
promote cancer cell growth and survival (Zahir et al., 2003). Of
note, a previous proteomic study showed that the expression
of α6β4 integrin in TNBC-secreted exosomes was positively
associated with lung metastasis of TNBC cells (Hoshino et al.,
2015). Although we did not detect specific α6β4 integrin in
our study, the down-regulation of laminin subunit alpha-5
responsive to DET or DETD-35 treatment may attenuate its
interaction with integrin proteins and further abrogate TNBC cell
proliferation, migration, lung metastasis among other activities
we observed previously in vitro or in vivo (Nakagawa-Goto et al.,
2016).
Epidermal growth factor-like repeat and discoidin I-like
domain-containing protein 3 (EDIL-3) and lysyl oxidase
homolog 2 (LOXL2) were reported to facilitate cancer cell
migration and pre-metastatic niche formation which were also
down-regulated in the DET or DETD-35 responsive exosomes.
EDIL-3 could activate EGF receptor (EGFR) signaling to promote
bladder cell migration (Beckham et al., 2014), and lysyl oxidase
secreted by hypoxic breast tumor cells was considered to be a
crucial mediator of pre-metastatic niche formation (Erler et al.,
2009). The down-regulation of these proteins also supports, in
part, the modes of action of DET or DETD-35 against TNBC cell
activity.
On the basis of IPA toxicity list analysis, we may link
compound-responsive proteins with biological mechanisms
to accumulate more important information on the possible
pharmacological response or potential mechanisms of
DET or DETD-35 against TNBC cells. Intriguingly, a few
compound-responsive exosomal proteins such as S100A9,
S100A7, and glutamate-cysteine ligase modifier subunit (GCLM)
related to oxidative stress, and HSPB1 involved in decrease of
transmembrane potential of mitochondria were increased by
DET/DETD-35 treatment. The S100 proteins are a multigenic
family of calcium-modulated proteins, which interact with
various receptors, and transcription factors among other target
molecules involved in regulation of different biological processes
(Donato et al., 2013). Our proteomic data show that the protein
levels of S100A7 and S100A9 were upregulated in the exosomes
collected from DET-/DETD-35−treated TNBC cells. Previous
reports suggested that ROS production stimulates the expression
of S100A7 or S100A9, and the regulation of the NF-κB pathway
is involved in the induction of S100A7 (Carlsson et al., 2005).
We have shown previously that DET deregulated the NF-κB/IKK
signaling pathway known for its anti-inflammation as well
as anti-cancer cell activities in macrophages or TS/A breast
cancer cells. In addition, DET directly competes with DNA
binding to NF-κB protein (Huang et al., 2010, 2013). We thus
propose that up-regulation of S100A7 in exosomes originating
from compound−treated TNBC cells might be associated
with de-regulating NF-κB protein and the associated pathway,
thus being involved in compound-induced anti-TNBC cell
activity.
On the other hand, the up-regulation of compound-
responsive exosomal protein heat shock protein beta-1 (HSPB1)
can be reversed by ROS scavenger NAC pretreatment as validated
by western blotting. Extracellular HSPB1 has been reported to
have several functions, such as inducing cytokine production,
modulating immune response, or promoting cell migration and
proliferation by interacting with distinct receptors (Batulan et al.,
2016). The overexpression of intracellular HSPB1 by transfecting
HSPB1 expression vector in normal rat kidney (NRK)-52E cells
was observed to promote the expression of autophagosomal
marker protein microtubule-associated protein 1 light chain 3
(LC3) (Matsumoto et al., 2015). Very recently, we demonstrated
that both DET and DETD-35 can promote paraptosis-like cell
death in MDA-MB-231 cells through inducing the expression
of LC3 and facilitating autophagosome accumulation (Shiau
et al., 2017). We thus consider that up-regulation of HSPB1 in
exosomes might be attributed to the anti-TNBC cell activity of
DET and DETD-35.
In summary, this report shed light on the mechanisms of
action of the plant derived sesquiterpene lactone compound
DET and its derivative DETD-35 against TNBC cell activities.
Induction of ROS/oxidative stress is a crucial factor that affects
the release and activity of exosomes from cancer cells by altering
protein composition and functions which suppress cancer cell
viability. Whether or not the biogenesis of cancer cell-derived
exosomes can also be altered by the plant compound treatment
remains unclear and warrants further investigation.
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